On June 1, 2021, specialty pharmaceutical company Advanz Pharma Corp. Limited announced the completion of its sale to leading European private equity investor Nordic Capital for $846 million.
According to the deal, each Advanz Pharma shareholder will get $17.26 in cash per share of the company. This excludes Bybrook, the former shareholder of the company who opted for the alternative offer and whose shares were swapped for Topco B Shares.
